コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 reatment, 533 sustained ACS (excluding acute ST-segment-elevation myocardial infarction).
2 or bioresorbable scaffolds in patients with ST-segment elevation myocardial infarction.
3 cularization in patients presenting with non-ST-segment elevation myocardial infarction.
4 tion, cardiac arrest, cardiogenic shock, and ST-segment elevation myocardial infarction.
5 stents (BMS) in an all-comer population with ST-segment elevation myocardial infarction.
6 in treatment strategies in patients with non-ST-segment elevation myocardial infarction.
7 ry syndromes include unstable angina and non-ST-segment elevation myocardial infarction.
8 predictor of left ventricular remodeling in ST-segment-elevation myocardial infarction.
9 s among these patients in the setting of non-ST-segment-elevation myocardial infarction.
10 ut-of-hospital sudden death and hospitalized ST-segment-elevation myocardial infarction.
11 netic resonance data in patients after acute ST-segment-elevation myocardial infarction.
12 ut-of-hospital sudden death and hospitalized ST-segment-elevation myocardial infarction.
13 nd hospitalized ST-segment-elevation and non-ST-segment-elevation myocardial infarction.
14 ment in predicting functional recovery after ST-segment-elevation myocardial infarction.
15 percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction.
16 overy of dysfunctional segments acutely post ST-segment-elevation myocardial infarction.
17 al stents (BMS), especially in patients with ST-segment-elevation myocardial infarction.
18 coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction.
19 nium enhancement 6 to 9 days after the index ST-segment-elevation myocardial infarction.
20 ncrease in treatment times in the setting of ST-segment-elevation myocardial infarction.
21 ention (PPCI) is the treatment of choice for ST-segment-elevation myocardial infarction.
22 prit-only revascularization in patients with ST-segment-elevation myocardial infarction.
23 y bypass surgery (CABG) in patients with non-ST-segment-elevation myocardial infarction.
24 during percutaneous coronary intervention in ST-segment-elevation myocardial infarction.
25 ostic role of eosinophil cationic protein in ST-segment-elevation myocardial infarction.
26 imary percutaneous coronary intervention for ST-segment-elevation myocardial infarction.
27 lity of FFR measurement in patients with non-ST-segment-elevation myocardial infarction.
28 ostic role of eosinophil cationic protein in ST-segment-elevation myocardial infarction.
29 leterious effects of ischemia/reperfusion in ST-segment-elevation myocardial infarction.
30 early and late outcomes in patients with non-ST-segment-elevation myocardial infarction.
31 remodeling and dysfunction in patients after ST-segment-elevation myocardial infarction.
32 his new approach in high-risk patients after ST-segment-elevation myocardial infarction.
33 neous coronary intervention in patients with ST-segment-elevation myocardial infarction.
34 nt of left ventricular (LV) remodeling after ST-segment-elevation myocardial infarction.
35 ) predisposes patients to inducible VT after ST-segment-elevation myocardial infarction.
36 gnosis, particularly for older patients with ST-segment-elevation myocardial infarction.
37 ortality, specifically, in patients with non-ST-segment-elevation myocardial infarction.
38 at TRA may reduce mortality in patients with ST-segment-elevation myocardial infarction.
39 ombus aspiration during PCI in patients with ST-segment-elevation myocardial infarction.
40 on of major adverse cardiac events (MACE) in ST-segment-elevation myocardial infarction.
41 assessment of myocardial injury early after ST-segment-elevation myocardial infarction.
42 thrombectomy and PCI alone in patients with ST-segment-elevation myocardial infarction.
43 approach to emergency care for patients with ST-segment-elevation myocardial infarction.
44 opulmonary resuscitation in patients without ST-segment-elevation myocardial infarction.
45 iated with a reduction in infarct size after ST-segment-elevation-myocardial infarction.
46 to reduce infarct size (IS) in patients with ST-segment elevation myocardial infarctions.
47 % versus 26%), and presented more often with ST-segment-elevation myocardial infarction (10.9% versus
49 nessed arrest (84.6% versus 77.4%), and have ST-segment-elevation myocardial infarction (32.7% versus
50 omized (mean age 55+/-9 years; 75% male; 56% ST-segment elevation myocardial infarction; 38% non-ST-s
51 imarily due to an increase in acute cases in ST-segment elevation myocardial infarction (4.27, 2.28-8
52 SCAD patients more frequently presented with ST-segment elevation myocardial infarction (57% vs. 36%;
53 ent elevation myocardial infarction; 38% non-ST-segment elevation myocardial infarction; 6% unstable
56 per year, a smaller proportion were PCI for ST-segment-elevation myocardial infarction (8.4%) than i
57 dial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4
58 tal cardiac arrest patients (n=1078) without ST-segment-elevation myocardial infarction admitted to t
59 o determine if timing of cell delivery after ST-segment-elevation myocardial infarction affects recov
60 1-year cumulative survival for patients with ST-segment-elevation myocardial infarction aged >/=76 ye
61 ed versus angiography-guided primary PCI for ST-segment-elevation myocardial infarction among patient
64 cularization strategies in patients with non-ST-segment elevation myocardial infarction and multivess
65 led trials have suggested that patients with ST-segment elevation myocardial infarction and multivess
66 revascularization in clinical scenarios with ST-segment elevation myocardial infarction and non-ST-se
67 wn to have prognostic value in patients with ST-segment-elevation myocardial infarction and cardiac a
68 idities and were less likely to present with ST-segment-elevation myocardial infarction and cardiogen
69 complete revascularization in patients with ST-segment-elevation myocardial infarction and multivess
70 We prospectively enrolled 49 patients with ST-segment-elevation myocardial infarction and performed
71 eous coronary intervention for elective, non-ST-segment-elevation myocardial infarction and ST-segmen
72 nger age categories and in patients with non-ST-segment-elevation myocardial infarction and stable an
73 ) in the United States for patients with non-ST-segment-elevation myocardial infarction and the compa
74 formed in women, in patients presenting with ST-segment elevation myocardial infarction, and for emer
75 2015 included 120 cases; 75% presented with ST-segment-elevation myocardial infarction, and 80% had
76 O-PCI) in patients with multivessel disease, ST-segment-elevation myocardial infarction, and cardioge
77 coronary microcirculation in the setting of ST-segment-elevation myocardial infarction, and how they
78 percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction are at increa
80 rfusion times and mortality in patients with ST-segment-elevation myocardial infarction are influence
82 follow-up, and specifically in patients with ST-segment elevation myocardial infarction, are scarce.
83 ions in time to reperfusion in patients with ST-segment-elevation myocardial infarction as well as in
84 with ST between EES and BMS in patients with ST-segment-elevation myocardial infarction at 5 years.
85 riage of survivors of cardiac arrest without ST-segment-elevation myocardial infarction at the point
87 0; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coeffici
89 ents underwent CABG within 21 days after non-ST-segment-elevation myocardial infarction between Janua
90 ing analyses of patients with large anterior ST-segment-elevation myocardial infarctions, bone marrow
91 on of the infarct-related coronary artery in ST-segment-elevation myocardial infarction both with fib
92 suggest a potential benefit of colchicine in ST-segment-elevation myocardial infarction, but further
93 ong predictor of functional improvement post ST-segment-elevation myocardial infarction, but recovery
94 ikely to include high-risk features, such as ST-segment-elevation myocardial infarction, cardiogenic
95 scoring model was developed and validated on ST-segment-elevation myocardial infarction cohorts from
96 Tn concentrations even in the absence of non-ST-segment elevation myocardial infarction, concern has
97 entation in heart failure, presentation with ST-segment elevation myocardial infarction, creatinine c
99 Routine thrombus aspiration during PCI for ST-segment-elevation myocardial infarction did not impro
101 by 9254 operators at 1538 hospitals for non-ST-segment-elevation myocardial infarction from 2009 to
102 e assessed 5-year mortality in patients with ST-segment-elevation myocardial infarction from the Fren
103 art Association guidelines for patients with ST-segment-elevation myocardial infarction gives a class
104 without PCI or in those with a diagnosis of ST-segment elevation myocardial infarction (group by PCI
106 on-infarct-related arteries in patients with ST-segment elevation myocardial infarction has been demo
107 reperfusion therapy for patients with acute ST-segment-elevation myocardial infarction have been doc
108 ary artery blood flow in patients with acute ST-segment-elevation myocardial infarction; however, fai
110 transfusion) among 99 200 patients with non-ST-segment elevation myocardial infarction in the Nation
111 ive sample of patients in China admitted for ST-segment-elevation myocardial infarction in 2001, 2006
112 Association reperfusion time guidelines for ST-segment-elevation myocardial infarction in a prospect
113 cerebrovascular events within 3 years after ST-segment-elevation myocardial infarction in patients u
114 -hospital cardiac arrest in patients without ST-segment-elevation myocardial infarction in the Copenh
115 ely 4% to 5%, a figure comparable to that of ST-segment-elevation myocardial infarction in the era of
116 Morphine is recommended in patients with ST-segment-elevation myocardial infarction, including th
117 June 2010 and September 2011 in Ontario for ST-segment-elevation myocardial infarction, including ti
118 left ventricular and clinical outcomes after ST-segment-elevation myocardial infarction independently
119 -segment-elevation myocardial infarction and ST-segment-elevation myocardial infarction indications i
120 ation myocardial infarction (group by PCI or ST-segment elevation myocardial infarction interaction e
121 of limiting the extent of necrosis during an ST-segment elevation myocardial infarction is of great i
122 rcutaneous coronary intervention (P-PCI) for ST-segment elevation myocardial infarction is uncertain.
123 rimary percutaneous coronary intervention in ST-segment-elevation myocardial infarction is a serious
125 ated heparin monotherapy in patients without ST-segment-elevation myocardial infarction is not well d
128 rvention (MIMI) trial, patients (n=140) with ST-segment-elevation myocardial infarction </=12 hours w
129 In a multicenter study, 120 patients with ST-segment elevation myocardial infarctions (<6 h) sched
130 s of cerebrovascular events in patients with ST-segment-elevation myocardial infarction managed with
132 s coronary intervention in 283 patients with ST-segment-elevation myocardial infarction (mean+/-SD ag
133 e success of coronary reperfusion therapy in ST-segment-elevation myocardial infarction (MI) is commo
135 ery disease (FFR</=0.8) in patients with non-ST-segment-elevation myocardial infarction (n=21) who un
137 cardial infarction (n=5996, 853 deaths), non-ST-segment-elevation myocardial infarction (n=5371, 901
138 ive survival was estimated for patients with ST-segment-elevation myocardial infarction (n=5996, 853
139 sible effect in patients with early anterior ST-segment elevation myocardial infarctions need confirm
140 ndings support efforts to implement regional ST-segment-elevation myocardial infarction networks focu
141 tervention (when indicated) in patients with ST-segment elevation myocardial infarction, no guideline
142 also common in matched control subjects with ST-segment-elevation myocardial infarction not having ha
143 lder than 18 years with unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or S
144 are no trials assessing thrombectomy in non-ST-segment elevation myocardial infarction (NSTEMI) pati
145 in CD4(+) T cells from 20 patients with non-ST-segment elevation myocardial infarction (NSTEMI), 20
146 d clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI).
147 ed patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI).
148 r the care and outcomes of patients with non-ST-segment elevation myocardial infarction (NSTEMI).
149 The trial included 9,326 patients with non-ST-segment elevation myocardial infarction (NSTEMI)/unst
151 vation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI) mana
152 on myocardial infarction [STEMI] and 241 non-ST-segment elevation myocardial infarction [NSTEMI] case
153 us Coronary Intervention on Occlusions After ST-Segment Elevation Myocardial Infarction; NTR1108).
154 In multivariable analyses, presentation with ST-segment elevation myocardial infarction (odds ratio 2
155 % confidence interval: 2.92 to 3.06) and non-ST-segment elevation myocardial infarction (odds ratio:
156 coronary artery disease presenting with non-ST-segment-elevation myocardial infarction, only one thi
157 CI: 0.62 to 0.91), and those presenting with ST-segment elevation myocardial infarction (OR: 0.63, 95
158 % confidence interval, 2.88-7.95; P<0.0001), ST-segment-elevation myocardial infarction (OR, 2.10; 95
159 47 was associated inversely with smoking and ST-segment-elevation myocardial infarction (P=0.004; odd
161 currently recommended antiplatelet agents in ST-segment-elevation myocardial infarction patients acco
162 (FDG) for glucose uptake was performed in 21 ST-segment-elevation myocardial infarction patients at a
163 patients, the healing pattern in event-free ST-segment-elevation myocardial infarction patients diff
165 r obstruction, which occurs in around 50% of ST-segment-elevation myocardial infarction patients post
166 ates in the PI and pPCI arms were similar in ST-segment-elevation myocardial infarction patients pres
167 sence of intramyocardial hemorrhage (IMH) in ST-segment-elevation myocardial infarction patients repe
168 phy and magnetic resonance in the reperfused ST-segment-elevation myocardial infarction patients show
169 ses were searched for trials that randomized ST-segment-elevation myocardial infarction patients to a
170 mplete Revascularization), we randomized 627 ST-segment-elevation myocardial infarction patients to f
171 provides better prognostic stratification of ST-segment-elevation myocardial infarction patients trea
176 ND In this prospective study, 88 consecutive ST-segment-elevation myocardial infarction patients were
178 in serum levels were significantly higher in ST-segment-elevation myocardial infarction patients with
179 reserve-guided complete revascularization in ST-segment-elevation myocardial infarction patients with
180 METHODS AND Hospitals (n=167 with 23 498 ST-segment-elevation myocardial infarction patients) wer
182 ognostic value over clinical risk factors in ST-segment-elevation myocardial infarction patients.
183 the area at risk delineated by T2 mapping in ST-segment-elevation myocardial infarction patients.
184 eventing adverse LV remodeling in reperfused ST-segment-elevation myocardial infarction patients.
185 stdischarge treatment of unstable angina/non-ST-segment-elevation myocardial infarction patients.
186 elop and validate a CMR-based risk score for ST-segment-elevation myocardial infarction patients.
187 idelines (ACTION-GWTG) database, we examined ST-segment-elevation myocardial infarction performance m
188 In this study of unselected patients with ST-segment-elevation myocardial infarction, PPCI during
189 rior studies demonstrated that patients with ST-segment-elevation myocardial infarction presenting du
191 verweight and obese older patients after non-ST-segment-elevation myocardial infarction relative to t
192 esenting with cardiogenic shock complicating ST-segment-elevation myocardial infarction remains unkno
193 versus placebo in 120 patients with anterior ST-segment-elevation myocardial infarctions resulting in
195 vely enrolled 27 patients with anterior wall ST segment elevation myocardial infarction (STEMI) and 4
196 se 2, a 49-year-old gentleman presented with ST segment elevation myocardial infarction (STEMI) and h
197 elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), with
198 isting bleeding definitions in patients with ST-segment elevation myocardial infarction (STEMI) and t
199 moral approaches in patients presenting with ST-segment elevation myocardial infarction (STEMI) and u
202 coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has n
204 an alternative to mechanical reperfusion for ST-segment elevation myocardial infarction (STEMI) in se
205 percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may n
206 ical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or no
207 ly IV beta-blockers before PPCI in a general ST-segment elevation myocardial infarction (STEMI) popul
210 as long-term cause of death in patients with ST-segment elevation myocardial infarction (STEMI) remai
211 percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) treat
212 sis (ST) rate up to 3 years in patients with ST-segment elevation myocardial infarction (STEMI) treat
213 ovement in clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) treat
214 tor antagonists are delayed in patients with ST-segment elevation myocardial infarction (STEMI) under
215 percutaneous coronary intervention (PCI) of ST-segment elevation myocardial infarction (STEMI) were
216 assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who w
217 ingle-center center studies in patients with ST-segment elevation myocardial infarction (STEMI), a la
221 nous (IV) metoprolol reduces infarct size in ST-segment elevation myocardial infarction (STEMI).
222 e epicardial and microvascular flow in acute ST-segment elevation myocardial infarction (STEMI).
224 who have multivessel disease presenting with ST-segment elevation myocardial infarction (STEMI).
225 ercutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
226 imary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).
227 rtensive patients, and those presenting with ST-segment elevation myocardial infarction (STEMI).
228 percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
229 prove the clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI).
230 nts standard care for treating patients with ST-segment elevation myocardial infarction (STEMI).
231 antify the edema-based area-at-risk (AAR) in ST-segment elevation myocardial infarction (STEMI).
234 rtery bypass grafting (CABG) presenting with ST-segment-elevation myocardial infarction (STEMI) and u
235 imary percutaneous coronary intervention for ST-segment-elevation myocardial infarction (STEMI) are s
237 nary intervention (PCI) for the treatment of ST-segment-elevation myocardial infarction (STEMI) has b
238 ival for overweight and obese patients after ST-segment-elevation myocardial infarction (STEMI) has b
240 of persistent T2 hyperintensity after acute ST-segment-elevation myocardial infarction (STEMI) is un
241 percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI) patie
243 ogy, but data on their long-term outcomes in ST-segment-elevation myocardial infarction (STEMI) setti
244 e direct immediate intervention and therapy, ST-segment-elevation myocardial infarction (STEMI) victi
246 ardiac magnetic resonance (MR) imaging after ST-segment-elevation myocardial infarction (STEMI).
247 rognostic utility in patients after an acute ST-segment-elevation myocardial infarction (STEMI).
248 iated with adverse outcomes in patients with ST-segment-elevation myocardial infarction (STEMI).
250 nostic coronary angiography, of whom 281 (40 ST-segment elevation myocardial infarction [STEMI] and 2
251 ically lower in-hospital mortality after non-ST-segment-elevation myocardial infarction than their no
252 percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction, the door-to-
254 patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction, there may be
255 ected patients presenting with suspected non-ST-segment elevation myocardial infarction to the emerge
256 e analysis of bivalirudin versus UFH for non-ST-segment-elevation myocardial infarction to date, biva
257 MVO in a cohort of consecutive patients with ST-segment-elevation myocardial infarction treated with
258 agents in patients with unstable angina/non-ST-segment-elevation myocardial infarction treated with
261 CIN) is a serious condition in patients with ST-segment-elevation myocardial infarction treated with
262 nalyzed 10 095 consecutive patients with non-ST-segment-elevation myocardial infarction treated with
263 red left ventricular EF (</=40%) after acute ST-segment-elevation myocardial infarction treated with
264 t the time of diagnosis in patients with non-ST-segment elevation myocardial infarction) trial, 4,033
265 prasugrel, type of acute coronary syndrome (ST-segment elevation myocardial infarction, troponin pos
266 ontrast-induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Pr
267 d with reduced infarct size in patients with ST-segment-elevation myocardial infarction undergoing pe
268 ects of NAC on infarct size in patients with ST-segment-elevation myocardial infarction undergoing pe
269 s immediate stenting, in patients with acute ST-segment-elevation myocardial infarction undergoing pr
271 ed peritoneal lavage system in patients with ST-segment-elevation myocardial infarction undergoing pr
272 this observational analysis of patients with ST-segment-elevation myocardial infarction undergoing pr
275 ollow-up study, 181 patients presenting with ST-segment-elevation myocardial infarction, undergoing p
276 imary percutaneous coronary intervention for ST-segment-elevation myocardial infarction underwent ear
277 oing PCI for STEMI or other indications (non-ST-segment-elevation myocardial infarction, unstable ang
278 t-elevation myocardial infarction versus non-ST-segment-elevation myocardial infarction/unstable angi
279 orithm for rapid rule-out and rule-in of non-ST-segment elevation myocardial infarction using high-se
280 ts were stratified by procedural indication (ST-segment-elevation myocardial infarction versus non-ST
283 ormance measures in patients presenting with ST-segment-elevation myocardial infarction was high, reg
284 ES for percutaneous coronary intervention in ST-segment-elevation myocardial infarction was not assoc
285 neous coronary intervention in patients with ST-segment elevation myocardial infarction, we use hiera
286 ment elevation myocardial infarction and non-ST-segment elevation myocardial infarction were consider
287 y, Spain, and the Netherlands, patients with ST-segment elevation myocardial infarction were randomly
288 g with an acute coronary syndrome, including ST-segment-elevation myocardial infarction were enrolled
291 ary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction) were screene
292 with acute coronary syndrome with or without ST-segment elevation myocardial infarction who were abou
293 tion) in diabetes mellitus patients with non-ST-segment-elevation myocardial infarction who had angio
295 cept for those (n=78, 23.6%) presenting with ST-segment-elevation myocardial infarction who underwent
296 ar (24.2%), but proportionally more were for ST-segment-elevation myocardial infarction with cardioge
299 119 matched patients hospitalized for acute ST-segment-elevation myocardial infarction without cardi
300 ting stent implantation in patients with non-ST-segment-elevation myocardial infarction would provide
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。